Retatrutide Knee Osteoarthritis Trial Results Phase 3 GZBJ

Eli Lilly's phase 3 TRIUMPH-4 trial [1][2], part of the GZBJ master protocol [3], delivered striking retatrutide knee osteoarthritis trial results phase 3 GZBJ. Patients with obesity and knee osteoarthritis saw an average 28.7% weight loss at the highest dose [1], alongside a roughly 76% reduction in knee pain scores after 68 weeks [1]. These topline results, announced in December 2025 [1], highlight retatrutide's potential as a triple hormone agonist for tackling both weight and joint pain, though full data and approval are still pending.

Introduction to Retatrutide Knee Osteoarthritis Trial Results Phase 3 GZBJ

Retatrutide knee osteoarthritis trial results phase 3 GZBJ represent a major step forward in treating obesity-related joint issues. This trial, known as TRIUMPH-4 [1][2], tested Eli Lilly's experimental drug in patients struggling with excess weight and knee pain. The findings could change how doctors approach this common problem.

What is Retatrutide and Its Mechanism of Action?

Retatrutide, or LY3437943, is a first-in-class triple agonist [1][2]. It targets three key receptors: GIP, GLP-1, and glucagon [1][2].

• **